DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-Small-Cell Lung Cancer

被引：0
|
作者：
Li, G. [1 ,2 ]
Su, P. [3 ]
Wang, S. [4 ]
Zhang, Y. [4 ]
Pang, J. [4 ]
Ou, Q. [4 ]
Shao, Y. [4 ]
Yu, H. [5 ]
Wang, X. [1 ,2 ]
机构：
[1] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Chengdu, Peoples R China
[2] Chinese Acad Sci, Sichuan Translat Med Res Hosp, Chengdu, Peoples R China
[3] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China
[4] Nanjing Geneseeq Technol Inc, Nanjing, Peoples R China
[5] Chengdu Jinniu Dist Peoples Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
DOT1L; Immune checkpoint inhibitors; Next-generation sequencing;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.21-17
引用
收藏
页码：S242 / S242
页数：1
相关论文
共 50 条
  • [1] Predictive value of DOT1L mutations for clinical outcomes in non-small-cell lung cancer patients receiving immune checkpoint inhibitor therapy
    Guo, Tianxing
    Wang, Zhaofeng
    Wang, Song
    Zhang, Yaru
    Pang, Jiaohui
    Ying, Yajun
    Ou, Qiuxiang
    Shen, Dong
    Li, Gang
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (10):
  • [2] Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer
    Kubo, Toshio
    Ichihara, Eiki
    Harada, Daijiro
    Inoue, Koji
    Fujiwara, Keiichi
    Hosokawa, Sinobu
    Kishino, Daizo
    Kawai, Haruyuki
    Ochi, Nobuaki
    Oda, Naohiro
    Hara, Naofumi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    RESPIRATORY INVESTIGATION, 2023, 61 (05) : 643 - 650
  • [3] Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer
    Hakozaki, Taiki
    Hosomi, Yukio
    Kitadai, Rui
    Kitagawa, Shingo
    Okuma, Yusuke
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (11) : 2957 - 2966
  • [4] Efficacy of Immune Checkpoint Inhibitor Monotherapy for Patients With Massive Non-Small-Cell Lung Cancer
    Hakozaki, T.
    Kitadai, R.
    Kitagawa, S.
    Hosomi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S520 - S521
  • [5] Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer
    Taiki Hakozaki
    Yukio Hosomi
    Rui Kitadai
    Shingo Kitagawa
    Yusuke Okuma
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 2957 - 2966
  • [6] Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer
    Wang, Xinan
    Ricciuti, Biagio
    Alessi, Joao, V
    Nguyen, Tom
    Awad, Mark M.
    Lin, Xihong
    Johnson, Bruce E.
    Christiani, David C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (12): : 1761 - 1769
  • [7] RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer
    Hopkins, Ashley M.
    Kichenadasse, Ganessan
    Logan, Jessica M.
    Rowland, Andrew
    Sorich, Michael J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (03): : 475 - 476
  • [8] Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
    Oya, Yuko
    Kuroda, Hiroaki
    Nakada, Takeo
    Takahashi, Yusuke
    Sakakura, Noriaki
    Hida, Toyoaki
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (07)
  • [9] RE: Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer Response
    Wang, Xinan
    Ricciuti, Biagio
    Alessi, Joao, V
    Nguyen, Tom
    Awad, Mark M.
    Lin, Xihong
    Johnson, Bruce E.
    Christiani, David C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (03): : 477 - 478
  • [10] Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer
    Schiwitza, Annett
    Schildhaus, Hans-Ulrich
    Zwerger, Birgit
    Rueschoff, Josef
    Reinhardt, Christian
    Leha, Andreas
    Andreas, Stefan
    Rittmeyer, Achim
    IMMUNOTHERAPY, 2019, 11 (09) : 769 - 782
12345